Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561 PHASE3 ACTIVE_NOT_RECRUITING

The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.

Details

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	12
Start date	Sat Jun 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Generalized Myasthenia Gravis
• gMG

Interventions

• Ravulizumab

Countries

Italy, Japan, Serbia, Switzerland, United States